Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Update re bioMSAR Testing at Aquafuel Research Ltd
Quadrise (AIM:QFI), the supplier of MSAR® and bioMSAR™ emulsion technology and fuels, is pleased to confirm the results of the latest bioMSAR™ testing at Aquafuel Research Ltd's ("Aquafuel") UK test facility.
The results relate to further engine optimisation testing of bioMSAR™, conducted on the Company's Cummins high-speed 4-stroke diesel engine generating set, to allow accurate performance monitoring, optimisation and measurements to be made. They follow the initial testing at Aquafuel, the results of which were published by the Company on 1 February 2021.
During 2021 the engine was modified to allow injection timing to be advanced and performance to be monitored more accurately. These enhancements provided the ability to assess and optimise engine efficiency and emissions whilst using bioMSAR™ and other fuels.
Initial baseline runs under the latest testing were undertaken to ensure prior bioMSAR™ performance results were repeatable. These confirmed previously announced engine efficiency benefits of 3% and reductions of Nitrogen Oxide ("NOx") emissions of over 20% in comparison to diesel fuel.
The next phase of testing now completed has demonstrated that by advancing injection timing, engine efficiency can be increased by over 13%, thereby further reducing fuel consumption and carbon dioxide ("CO2") emissions.
Ordinarily, higher engine efficiencies result in increased combustion temperatures and NOx emissions. However, of particular note, the latest tests at Aquafuel have confirmed that it was possible with bioMSAR™ to reduce the inlet air temperature to the same level as diesel. This resulted in NOx levels being further reduced by over 30%, some 45% lower than diesel fuel.
These latest tests have therefore shown that much higher diesel engine efficiency can be achieved with bioMSAR™, without increasing NOx emissions. Further tests are being planned with Aquafuel during the year to focus on fully defining efficiency and emissions optimisation settings.
Update on COVIDITY Phase 1 clinical trial in South Africa
First patient dosed with second COVIDITY vaccine candidate (SCOV2)
Preclinical studies demonstrate strong immunity against Omicron
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces further progress of the Phase 1 COVIDITY clinical trial being conducted at the University of Cape Town (UCT) Lung Institute in South Africa.
The objectives of the first part of the trial are to assess the safety and immunogenicity of two vaccine candidates, SCOV1 and SCOV2, in healthy, vaccine-naïve subjects, prior to testing as a booster in volunteers who have already received an approved vaccine. To date, 16 subjects have been enrolled and the SCOV1 immunisations have been well tolerated, with no safety concerns. As per protocol, we can now report that the first subject has received their first injection with the second vaccine candidate SCOV2, following two injections with SCOV1.
As announced at the Company's interim results, due to the high case numbers of the Omicron variant in South Africa, recruitment has been slow to date but, now the country's wave of infections has passed, screening is continuing at an increased rate, with further safety and immunogenicity data still expected to be available in H1 2022.
Scancell has previously shown in preclinical models that both SCOV1 and SCOV2 induce high titre antibodies and potent T cells against both the S and N antigens, and that these responses cross-reacted with the Delta variant. The Company has now confirmed in preclinical studies that although both vaccines induced responses against the Omicron variant, the strongest responses were seen with SCOV2.
Honorary Prof Rod Dawson, Managing Director of the University of Cape Town Lung Institute, commented: "There is still a need for additional SARS-CoV-2 vaccines that are safe and effective to achieve long-lasting protection against new and emerging variants. The UCT Lung Institute remains highly motivated to investigate the clinical potential of the SCOV1 and SCOV2 vaccines with our colleagues at Scancell."
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "We are delighted that the first subject has now received a SCOV2 injection in the COVIDITY Phase 1 clinical trial. The Scancell team and collaborators remain convinced that a more durable and broader-acting vaccine is required to combat the global pandemic and we are encouraged by the emerging data supporting the use of our vaccines against new variants."
Further to the announcement made on 14 January 2022, Minds + Machines Group Limited (AIM: MMX) is pleased to announce the results of its Tender Offer. The Tender Offer closed at 1.00pm on 28 January 2022.
The Company confirms the Tender Offer was fully subscribed and 182,692,308 Ordinary Shares will be purchased at a price of 10.4 pence per Ordinary Share, for an aggregate consideration of £19 million. Tenders for up to and including the Tender Offer Entitlement of 1 Ordinary Share for every 1.49 Ordinary Shares held by a shareholder will be met in full representing approximately 89.68% of the Ordinary Shares being purchased by the Company. The remaining 10.32% of the Ordinary Shares being bought back under the Tender Offer, will be purchased on the basis of 1 Ordinary Share for every 12.91 Ordinary Shares tendered, pursuant to demand for Excess Shares by Eligible Shareholders. The Ordinary Shares to be purchased under the Tender Offer represent approximately 67.3% of the current Ordinary Shares in issue.
· Recently completed geological mapping indicates that the target horizon hosting high-grade manganese may extend continuously for at least 4km between the Loltware and Moshaneng prospects
· The mineralised horizon lies at the same stratigraphic level as the Giyani Metals' K-Hill project located just to the south-east from Bezant's licence
· A follow-up programme of soil sampling and trenching is planned to commence in the coming week to test the continuity of the manganese target
· A preliminary plan has been prepared for drill testing in the vicinity of the Moshaneng Borrow Pit, to be finalised based on results of the soil/trenching programme
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that the University of Queensland has informed the Company that it has been notified by the US patent attorney of the granting of its patent application in relation to Nuvec® in the United States and by the Chinese authorities of the granting of a patent in China. N4 Pharma has the exclusive worldwide rights to Nuvec® for therapeutic uses in humans and animals.
The granted patent in the USA will specifically cover the matter of composition of the nanoparticle made using a broad description of the manufacturing process used by the Company. The University of Queensland has also informed the Company it will file a continuation patent application in the USA for a matter of composition patent independent of the manufacturing process to match the patents granted in Europe, Japan, Australia and China.
Nigel Theobald, Chief Executive Officer of the Company, commented: "We are delighted to receive notification of this allowance to grant our licensed patent in these critical and influential markets.
"The granting of this USA nanoparticle patent using a broad description of the manufacturing process adds to the other granted patents giving us strong intellectual property protection in the key territories across the world which is a vital component for potential licensing deals"
Xpediator (AIM: XPD), a leading provider of freight management services across the UK and Central and Eastern Europe, is pleased to confirm trading, for the 12 months to 31 December 2021, has continued strongly across all three divisions and expects to deliver revenues in excess of £300 million (2020: £221 million) and adjusted profit before tax well in excess of £8.5 million (2020: £7.2 million), in line with the upgraded guidance given in June 2021.
Revenue growth continued into the second half of 2021, with strong increases in Freight Forwarding revenues, the largest division of the Group, driven primarily by CEE markets, increased sea freight volumes and an uplift from UK customs clearance. Lithuania and Bulgaria are again expected to be significant contributors to the uplift in performance.
Pallex Romania has contributed to another positive trading period for the Logistics and Warehousing division. In addition, the recent partnership with e-Commerce fulfilment expert, Synergy Retail Support, has introduced new customers into the Braintree site (Essex) and other Xpediator warehouses.
Something happening at the Venus site today
Similar movement to what happen at the Graff well site before the oil and gas discovery
Supply ships going up and down Welvis Bay port
Pacific Gull Vessel on the way to Welvis Bay and the Pacific Legend vessel arrives at Venus 1X well site
Interesting
https://www.shiplocation.com/vessels/MAERSK-VOYAGER/CURRENT-POSITION/9633575
That was a strong close on Friday
Funding not needed short term confirmed
Lets roll on 0.50 first target next week
Asiamet Resources Limited ("Asiamet" or the "Company") refers to the market announcement made on 3 November 2021 in relation to the Company entering into a non-binding Heads of Agreement ("HoA") with PT Delta Dunia Makmur Tbk. ("DOID").
The HoA, subject to finalisation of due diligence and conditions precedent, would see DOID contribute $50 million (on a staged basis) towards the development of the BKM copper project, in exchange for an interest of up to 51% in Asiamet's wholly owned subsidiary, Indokal Limited. Indokal Limited is the owner of the KSK Contract of Work, located in Central Kalimantan, Indonesia.
Under the terms of the HoA, an initial exclusivity period of 90 days was provided to allow DOID to complete due diligence. In parallel with the due diligence process, the Company has initiated discussions with a number of banks in relation to the project financing.
Whilst significant progress has been made with the consultants on all the key due diligence workstreams covering technical, legal, commercial financial and social governance. There have been several delays including COVID-19 deferring the DOID team's site review, and the availability of key consultants through the main holiday period in Australia.
As such, the parties have agreed to extend the exclusivity period to allow DOID to complete its due diligence. The parties are presently determining the timeframe required to finalise due diligence and execute transaction documentation. The Company will provide an update to the market as soon as possible.
Highlights:
· 1,422m of RC drilling completed, focusing mainly on the mineralised trend known as Nugget Patch which was prioritised based on previous exploration results showing a coherent supergene gold-enriched zone.
· At Teglio, additional holes were drilled to confirm historic high-grade gold intersections closely associated with the main workings, plus an additional traverse to test under a strong gold-in-soil anomaly recently defined by Empire some 300m northwest of the previous drilling
· Significant intercepts reported:
Ø 1m @ 1.35 g/t Au from 81m downhole at Nugget Patch
Ø 2m @ 1.41 g/t Au from 90m downhole at Nugget Patch
Ø 3m @ 3.1 g/t Au from 13m downhole at Teglio (drilled 300m NW of old workings)
Ø 4m @ 1.12 g/t Au from 36m downhole at Teglio (drilled near old workings)
Nice and steady followed by a breakout in the afternoon